Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile at single cell level of CD45+ cells from AB1 mesothelioma treated with either vaccinia virus Tiantan strain or mock-treated

ABSTRACT: Gene expression profile at single cell level of CD45+ cells from AB1 mesothelioma treated with either vaccinia virus Tiantan strain or mock-treated

PROVIDER: PRJNA915321 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profile at single cell level of CD45+ cells from AB1 mesothelioma treated with either vaccinia virus Tiantan strain or mock-treated

Project description:To understand the immune infiltrates in the tumor microenvironment in response to vaccinia virotherapy, we used single cell RNA sequencing (scRNAseq) to analyze the diversity of total CD45+ isolated from AB1 mesothelioma

2023-12-01 | GSE221653 | GEO

Genexpression of murine mesothelioma cell lines AC29 and AB1

Project description:RNA from two murine mesothelioma cell lines (AC29 and AB1) was extracted and hybridized to Affymetrix Microarrays to compare gene expression. Both mesothelioma cell lines were established following intraperitoneal introduction of crocidolite (asbestos) fibers (Davis et al. 1992) in CBA mice (AC29 cell line), and BALB/c mice (AB1).

2017-03-29 | GSE97150 | GEO

Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin and immune checkpoint therapy

Project description:Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin, immune checkpoint therapy or the combination of tretinoin+immune checkpoint therapy.

2022-03-17 | GSE186195 | GEO

Bulk RNAseq of AB1-HA murine mesothelioma tumors from complete responders and partial responders to cyclophosphamide chemotherapy

Project description:Purpose: To compare the gene expression profiles of tumors from complete responders and partial responders to cyclophosphamide chemotherapy. AB1-HA murine mesothelioma tumors were excised one day prior to cyclophosphamide or three or seven days post cyclophosphamide.

2022-08-18 | GSE182674 | GEO

Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma

Project description:Regional delivery of oncolytic viruses has been shown to promote immune responses. Malignant pleural effusions comprise an immunosuppressive microenvironment, and the ability of oncolytic viruses to generate immune responses following regional delivery in patients with malignant pleural effusions is unknown. We conducted a phase I clinical trial that studied the intrapleural administration of oncolytic vaccinia virus to establish the safety and feasibility in patients with malignant pleural effusion due to malignant pleural mesothelioma or metastatic disease. In patients with malignant pleural mesothelioma, by correlative analysis of pre- and post-treatment tumor biopsies, we provide insight into tumor-specific viral uptake and associated immune responses.

2023-01-27 | GSE223395 | GEO

Mesothelioma xenografts in nude mice: PBS treated versus pirfenidone treated

Project description:Background: Malignant mesothelioma is an aggressive cancer with poor prognosis. It is characterized by prominent extracellular matrix, mesenchymal tumor cell phenotypes and chemoresistance. In this study, the ability of pirfenidone to alter mesothelioma cell proliferation and migration as well as mesothelioma tumor microenvironment was evaluated. Pirfenidone is an anti-fibrotic drug used in the treatment of idiopathic pulmonary fibrosis and has also anti-proliferative activities. Aims: Transcriptional profiling using RNA sequencing of human mesothelioma xenograft tumors treated with PBS or pirfenidone. Aim was to compare extracellular matrix and fibrosis related genes. Results: Treatment of mice harboring mesothelioma xenografts with pirfenidone alone did not reduce tumor proliferation in vivo. However, pirfenidone modified the tumor microenvironment by reducing the expression of extracellular matrix associated genes. In addition, GREM1 expression was downregulated by pirfenidone in vivo. Conclusion: By reducing two major upregulated pathways in mesothelioma and by targeting tumor cells and the microenvironment pirfenidone may present a novel anti-fibrotic and anti-cancer adjuvant therapy for mesothelioma.

2018-12-14 | GSE113803 | GEO

Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin and immune checkpoint therapy

Project description:Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin and immune checkpoint therapy

| PRJNA772938 | ENA

H2-ab1 Mouse Parent of Origin

Project description:We looked for parent of origin effects on genome-wide gene expression in a reciprocal cross between C57BL/6J x B6(C)-H2bm12/KhEgJ mice (the latter strain is a knockout of H2-ab1 on a C57BL/6J background). The aim is to find genes whose expression is altered in trans depending on whether the mother or father carried a knockout allele for H2-ab1. In this experiment differential expression of a gene is inferred from a difference in its overall expression levels. We sequenced RNA from 30 F1 mice from the H2-ab1 heterozygous cross. Both heterozygous and wild type F1 animals were sequenced in order to find both parental and parent of origin effects. We measured expression in the lungs (average 6.2 million reads per sample) and hippocampus (6.6 million reads).

2013-11-01 | E-MTAB-1998 | biostudies-arrayexpress

Mesothelioma xenografts in nude mice: PBS treated versus pirfenidone treated

Project description:Mesothelioma xenografts in nude mice: PBS treated versus pirfenidone treated

| PRJNA454010 | ENA

Bulk RNAseq of AB1-HA murine mesothelioma tumors from immunocompetent or CD4+ T cell depleted mice.

Project description:Bulk RNAseq of AB1-HA murine mesothelioma tumors from immunocompetent or CD4+ T cell depleted mice.

| PRJNA756568 | ENA